← All trials
NCT04450329
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 23, 2020
- Primary completion
- Mar 8, 2021
- Completion date
- Feb 14, 2022
- First posted
- Jun 29, 2020
- Last posted
- Jun 29, 2020
- Enrollment
- 446
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- SamsungLead sponsor
- Seoul National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.